Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 25;14:2121–2130. doi: 10.2147/OTT.S242224

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Gmeiner.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Summary of biomarker-based stratification to identify optimal front-line treatment for mCRC patients. Screening for KRAS/NRAS and BRAF activating mutations and for high MSI and deficiencies in MMR is recommended by the NCCN prior to treatment. %-positive indicates percent of patients that test positive for the biomarker indicated.

Abbreviations: FP, fluoropyrimidine; FOLFOXFIRI, folinic acid, 5-fluorouracil, oxaliplatin, irinotecan; MMR, mismatch repair; MSI, microsatellite instability; NGS, next generation sequencing; PD1, programmed cell death 1; PDL1, programmed death ligand 1; RTK, receptor tyrosine kinase.